Who can use Cyramza(Ramucirumab)?

Ramucirumab is a recombinant humanized IgG1 monoclonal antibody that specifically targets and binds to vascular endothelial growth factor receptor 2 (VEGFR2). 

Who can use Cyramza(Ramucirumab)?

It inhibits the binding of ligands such as VEGF-A, VEGF-C, and VEGF-D to VEGFR2, thereby blocking the tumor angiogenesis signaling pathway. Through this mechanism, ramucirumab effectively suppresses VEGFR2-mediated endothelial cell proliferation, migration, and new blood vessel formation, thus inhibiting tumor growth and metastasis.

Multiple clinical studies have confirmed that ramucirumab demonstrates significant antitumor effects in advanced gastric cancer, non-small cell lung cancer, colorectal cancer, hepatocellular carcinoma, and other cancer types. It particularly shows remarkable efficacy in patients who have progressed after receiving platinum or fluorouracil-based chemotherapy.